Radiation Therapy Is a Reasonable Option for Improving the Prognosis in XXXX .

@entity1161 @entity1 @entity157
@entity1161 ( @entity1161 ) may be suitable for treating @entity1 with @entity157 ( @entity157 ) who are difficult to treat with any other option. However, it remains unclear whether @entity1161 extends survival in these @entity1 . Among the 957 @entity157 @entity1 treated at Tohoku University Hospital from January 2007 to December 2013, only 49 @entity1 received @entity1161 . We therefore retrospectively analyzed the outcomes of these @entity1 ; they were divided into three groups based on the reasons for choosing @entity1161 : 27 @entity1 at Stage IV A (67.1    1.6 years, 50.5    2.1 Gy), 9 @entity1 with alternative therapy (72.2    2.4 years, 58.9    1.1 Gy), and 13 @entity1 who received @entity1161 after transarterial chemoembolization (TACE) (75.6    2.1 years, 56.5    1.5 Gy). @entity1161 was employed to ensure the local control of the lesion. The @entity1 at Stage IV A were treated with radical @entity1161 (n = 16) or with palliative @entity1161 (n = 11). In radical @entity1161 group, the response rate was 37.5% and the complete response rate was 25%. The survival rate was 12.5    2.6 months after radical @entity1161 . This is considered relatively good for Stage IV A. The disease-free survival rate was 13.0    2.8 months after @entity1161 . This excellent disease-free survival indicates that @entity1161 is an alternative to other treatments. In the TACE group, @entity1 who received the @entity1161 had the significantly long disease-free survival rate than only-TACE (18.0    3.8 months vs. 11.2    0.58 months). We propose that @entity1161 is effective and safe for @entity157 .
